Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: Results of an observational study (EFESO study);Incidencia de síntomas extrapiramidales durante el tratamiento con olanzapina, haloperidol y risperidona: Resultados de un estudio observacional (EFESO)

Actas Espanolas de Psiquiatria

Volumn 29, Issue 1, 2001, Pages 25-32

  Sacristan J A ^a,e   Gomez J C ^a   Ferre, F ^b   Gascon J ^c   Perez Bravo A ^d   Olivares, J M ^d  

^a DCRandT   (Spain)

^b Centro de Salud de Alcobendas   (Spain)

^c HOSPITAL MÚTUA DE TERRASSA   (Spain)

^d HOSPITAL XERAL CÍES   (Spain)

^e ELI LILLY AND COMPANY   (Spain)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Haloperidol; Olanzapine; Risperidone; Safety; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE; RISPERIDONE;

ADULT; AMBULATORY CARE; ANALYSIS OF VARIANCE; ARTICLE; DRUG COMBINATION; DYSKINESIA; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SCHIZOPHRENIA;

ADULT; AMBULATORY CARE; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG THERAPY, COMBINATION; DYSKINESIAS; FEMALE; HALOPERIDOL; HUMANS; MALE; PATIENT COMPLIANCE; PIRENZEPINE; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA;

EID: 0035221748     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic non compliance. Psychiatr Ann 1986;16:571-5.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
3. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioceceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
4. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. Olanzapine: a basic science update. Br J Psychiatry 1999;174(Supl 37): 36-40.
5. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
6. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
7. Tollefson G, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-65.
8. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychoparmacol 1997;17:407-18.
9. Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998;59:26-30.
10. Gómez JC, Sacristán JA, Hernández J, Breier A, Ruiz P, Antón C, et al. The safety of olanzapine compared to other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study). J Clin Psychiatry 2000;61:335-43.
11. Lingjaerde O, Ahlors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptictreated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100.
12. National Institute of Mental Health. Clinical Global Impressions. En: Guy E, ed. ECDEU Assessment for Psychopharmacology. Rev. Rockville, Md: National Institute of Mental Health; 1976.
13. th ed. Washington, DC: American Psychiatric Press; 1994.
14. Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 1999;60(Supl 8):21-8.
15. Barnes TRE, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psichiatry Suppl 1999; 38:34-43.
16. Beasley CM. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174: 23-30.
17. Tollefson GD. Blind, controlled, long-term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-54.
18. Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-90.
19. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psichiatry 1997;58:205-11.
20. Leucht S, Pitschel-Walz G, Abraham D, Kissling AW. Efficacy and extrapiramidal side-effects of the new antipsychotics olanzapine, quetapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizoph Res 1999;35:51-68.
21. Chouinard G, Kopala L, Labelle A, Beauclair L, Johnson SV, Singh KI, and the RIS-CAN Study Group. Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. Can J Psychiatry 1998;43:1018-25.